{"id":11619,"date":"2021-01-19T16:12:35","date_gmt":"2021-01-19T10:42:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11619"},"modified":"2021-07-24T12:58:14","modified_gmt":"2021-07-24T07:28:14","slug":"pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen","title":{"rendered":"Biohaven&#8217;s Troriluzole Failure; Daiichi\/ AZ&#8217;s Enhertu; Fujifilm &#038; Manufacturing Spree; J&#038;J&#8217;s Darzalex Faspro"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f2213228943\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f2213228943\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen\/#Biohavens_Troriluzole_Dwindles_Again_In_Alzheimers_After_Anxiety\" >Biohaven&#8217;s Troriluzole Dwindles Again In Alzheimer\u2019s After Anxiety&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen\/#A_Sweet_Year_For_Daiichi_AZ_As_Enhertu_Gets_FDA_Approval_For_Gastric_Cancer\" >A Sweet Year For Daiichi\/ AZ As Enhertu Gets FDA Approval For Gastric Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen\/#Fujifilm_Increases_Legroom_In_Cell_And_Gene_Therapy_Plans_For_New_Manufacturing_Facility\" >Fujifilm Increases Legroom In Cell And Gene Therapy, Plans For New Manufacturing Facility&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen\/#J_Js_Darzalex_Faspro_Receives_FDAs_Blessings_For_Amyloidosis\" >J&amp;J&#8217;s Darzalex Faspro Receives FDA\u2019s Blessings For Amyloidosis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biohavens_Troriluzole_Dwindles_Again_In_Alzheimers_After_Anxiety\"><\/span><strong>Biohaven&#8217;s Troriluzole Dwindles Again In Alzheimer\u2019s After Anxiety&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Biohaven Pharmaceuticals had put too much faith in its third-generation prodrug, <strong>Troriluzole<\/strong>. The company has tested the efficacy of the drug in more than one indication, including generalized anxiety disorder (GAD), obsessive-compulsive disorder, spinocerebellar ataxia and Alzheimer\u2019s disease (AD). However, it seems the drug continues to disappoint the company one after another.<\/p>\n\n\n\n<p>After the drug failed to produce better outcomes in anxiety, failed to meet primary outcomes in OCD, the company announced that their chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body, has even flunked in Phase 2\/3 clinical trial as a symptomatic treatment in mild-to-moderate <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Alzheimer&#8217;s disease<\/a> <\/strong>(AD).\u00a0<\/p>\n\n\n\n<p>Thus, the company has decided to wrap up the trials for AD. This is not something new in the <a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/\" target=\"_blank\" rel=\"noreferrer noopener\">Alzheimer\u2019s disease market<\/a>. Despite the availability of scientific evidence, extensive R&amp;D, and investment of huge amounts, <strong>no new drug<\/strong> has managed to walk the carpets. Several have failed and abandoned with the plight and the cost of the disease seemingly growing with each year passing.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_Sweet_Year_For_Daiichi_AZ_As_Enhertu_Gets_FDA_Approval_For_Gastric_Cancer\"><\/span><strong>A Sweet Year For Daiichi\/ AZ As Enhertu Gets FDA Approval For Gastric Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The U.S. Food and Drug Administration has given the nod to Daiichi Sankyo\u2019s and AstraZeneca\u2019s Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.<\/p>\n\n\n\n<p><strong>Enhertu <\/strong>is an antibody-drug conjugate (ADC) that comprises a humanized anti-HER2 IgG1 monoclonal antibody. The approval is based on the positive results from the randomised Phase 2 trial conducted in Japan and South Korea.&nbsp;<\/p>\n\n\n\n<p>With the approval, Enhertu has become the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">gastric cance<\/a>r. It is already approved for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.\u00a0 The company has future plans to pursue the trials for the drug across a broad range of HER2 targetable cancers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fujifilm_Increases_Legroom_In_Cell_And_Gene_Therapy_Plans_For_New_Manufacturing_Facility\"><\/span><strong>Fujifilm Increases Legroom In Cell And Gene Therapy, Plans For New Manufacturing Facility&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Fujifilm and the Center for Advanced Biological Innovation and Manufacturing (CABIM) has secured USD 76 million in financing and also signed a lease for a 40,000 square-foot site in Watertown, Massachusetts at The Arsenal on the Charles, owned and operated by Alexandria Real Estate Equities.&nbsp;<\/p>\n\n\n\n<p>CABIM, the industry-academia research and development consortium, is a joint effort of Fujifilm, Harvard University, Massachusetts Institute of Technology, Cytiva (formerly part of GE Healthcare Life Sciences), and Alexandria Real Estate Equities, Inc. CABIM plans to help make new therapeutics, medicines, and technologies accessible to patients and strengthen Greater Boston&#8217;s position as the <strong>world&#8217;s life science capital.<\/strong> The plan is to build eight clean rooms, with a configuration to produce both cell and viral vector products within the physical space.&nbsp;<\/p>\n\n\n\n<p>Fujifilm is trying everything to build its position in the <a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">cell and gene therapy<\/a> domain even stronger. With its CDMO arm, Fujifilm Diosynth Biotechnologies exploring more in-depth into the domain, and showing a shited interest in its viral vector capabilities for Covid-19 vaccines, will procure GMP2 contract process development and manufacturing services as part of its role in the new manufacturing and innovation centre.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"J_Js_Darzalex_Faspro_Receives_FDAs_Blessings_For_Amyloidosis\"><\/span><strong>J&amp;J&#8217;s Darzalex Faspro Receives FDA\u2019s Blessings For Amyloidosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Janssen has announced that its <strong>Darzalex Faspro<\/strong> has received the USFDA approval for adults with newly diagnosed light chain amyloidosis. The drug was originally developed by Genmab in 2012 and was in-licensed to Janssen.&nbsp;<\/p>\n\n\n\n<p>Darzalex Faspro is a combination of daratumumab and hyaluronidase-fihj, a subcutaneous formulation of daratumumab. It is the only CD38-directed antibody that has got approval for subcutaneous injection for multiple myeloma, and now it has been given the nod for <a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">AL amyloidosis<\/a>. The drug is approved in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) and is the first and only FDA-approved therapy for patients with this indication.\u00a0<\/p>\n\n\n\n<p>AL amyloidosis affects over 4000 people each year in the US, and about 30% of patients with AL amyloidosis die in the first year after diagnosis. Today\u2019s approval is nothing less than a breakthrough in the AL amyloidosis market.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biohaven&#8217;s Troriluzole Dwindles Again In Alzheimer\u2019s After Anxiety&nbsp; Biohaven Pharmaceuticals had put too much faith in its third-generation prodrug, Troriluzole. The company has tested the efficacy of the drug in more than one indication, including generalized anxiety disorder (GAD), obsessive-compulsive disorder, spinocerebellar ataxia and Alzheimer\u2019s disease (AD). However, it seems the drug continues to disappoint [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,16852,96,1635,16851,16853,258,16854],"industry":[17225],"therapeutic_areas":[17235,17229,17238,17245,17228,17234],"class_list":["post-11619","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-amyloidosis","tag-astrazeneca","tag-daiichi-sankyo","tag-enhertu","tag-fujifilm","tag-gene-therapy","tag-troriluzole","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-central-nervous-system","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biohaven&#039;s Troriluzole; Daiichi\/ AZ&#039;s Enhertu; Fujifilm Manufacturing Units<\/title>\n<meta name=\"description\" content=\"Biohaven&#039;s Troriluzole Failure in Alzheimer&#039;s; Daiichi\/ AZ&#039;s Enhertu; Fujifilm &amp; Manufacturing Spree; J&amp;J&#039;s Darzalex Faspro for Amyloidosis\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biohaven&#039;s Troriluzole; Daiichi\/ AZ&#039;s Enhertu; Fujifilm Manufacturing Units\" \/>\n<meta property=\"og:description\" content=\"Biohaven&#039;s Troriluzole Failure in Alzheimer&#039;s; Daiichi\/ AZ&#039;s Enhertu; Fujifilm &amp; Manufacturing Spree; J&amp;J&#039;s Darzalex Faspro for Amyloidosis\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T10:42:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/19160924\/Biohaven.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biohaven's Troriluzole; Daiichi\/ AZ's Enhertu; Fujifilm Manufacturing Units","description":"Biohaven's Troriluzole Failure in Alzheimer's; Daiichi\/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro for Amyloidosis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen","og_locale":"en_US","og_type":"article","og_title":"Biohaven's Troriluzole; Daiichi\/ AZ's Enhertu; Fujifilm Manufacturing Units","og_description":"Biohaven's Troriluzole Failure in Alzheimer's; Daiichi\/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro for Amyloidosis","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-01-19T10:42:35+00:00","article_modified_time":"2021-07-24T07:28:14+00:00","og_image":[{"width":750,"height":420,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/19160924\/Biohaven.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen","name":"Biohaven's Troriluzole; Daiichi\/ AZ's Enhertu; Fujifilm Manufacturing Units","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/19160924\/Biohaven.jpg","datePublished":"2021-01-19T10:42:35+00:00","dateModified":"2021-07-24T07:28:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Biohaven's Troriluzole Failure in Alzheimer's; Daiichi\/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro for Amyloidosis","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-fujifilm-biohaven-daiichi-janssen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/19160924\/Biohaven.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/19160924\/Biohaven.jpg","width":750,"height":420,"caption":"Biohaven's Troriluzole; Daiichi\/ AZ's Enhertu; Fujifilm Manufacturing Units"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/19160924\/Biohaven-300x168.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amyloidosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Daiichi Sankyo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Enhertu<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fujifilm<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Troriluzole<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Amyloidosis<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Daiichi Sankyo<\/span>","<span class=\"advgb-post-tax-term\">Enhertu<\/span>","<span class=\"advgb-post-tax-term\">Fujifilm<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Troriluzole<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 19, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 19, 2021 4:12 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Biohaven's Troriluzole; Daiichi\/ AZ's Enhertu; Fujifilm Manufacturing Units","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11619"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11619\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11622"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11619"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11619"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}